Phase I study of intravenous (IV) milataxel in adult patients with advanced malignant tumors.

被引：0
|
作者：
Bourbouloux, E.
Campone, M.
Vermorken, J. B.
Martin, M.
Sessa, C.
Perotti, A.
机构：
[1] Univ Antwerp Hosp, Antwerp, Belgium
[2] Hosp Clin Univ San Carlos, Madrid, Spain
[3] Osped San Giovani, Bellinzona, Switzerland
[4] Ist Nazl Tumori, I-20133 Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：88S / 88S
页数：1
相关论文
共 50 条
  • [31] A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors.
    Sandler, Alan
    Taylor, Matthew Hiram
    Urba, Walter John
    Omuro, Antonio Marcilio Padula
    Anderson, Barry Douglas
    Hansen, Daniel
    Fisher, Brenda
    Claeys, Alisa J.
    Greathouse, Amy
    McLean, Sean
    Karmali, Rashida A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] A phase I study of ARQ 197 in combination with temsirolimus in patients (Pts) with advanced stolid tumors.
    Braden, Amy M.
    Wisinski, Kari Braun
    Eickhoff, Jane C.
    Schelman, William R.
    Bailey, Howard Harry
    Mulkerin, Daniel
    Heideman, Jennifer
    Kolesar, Jill
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors.
    Townsley, C. A.
    Siu, L. L.
    Pedro-Salcedo, M. San
    Liu, L.
    Wakelee, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
    Liu, Lian
    Zhang, Wen
    Li, Wenhua
    Lv, Fangfang
    Xia, Zuguang
    Zhang, Sheng
    Liu, Wen
    Zandvliet, Anthe S.
    Waajen, Sylvia
    Zhang, Li Xin
    Yan, Li
    Li, Jin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [35] A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
    Lian Liu
    Wen Zhang
    Wenhua Li
    Fangfang Lv
    Zuguang Xia
    Sheng Zhang
    Wen Liu
    Anthe S Zandvliet
    Sylvia Waajen
    Li Xin Zhang
    Li Yan
    Jin Li
    Journal of Hematology & Oncology, 6
  • [36] Phase I clinical and pharmacokinetic study of irofulven in combination with oxaliplatin in patients with advanced solid tumors.
    Alexandre, J
    Tchen, N
    Berthault-Cvitkovic, F
    Misset, JL
    Benettaib, B
    Kahatt, C
    Raymond, E
    Weems, G
    MacDonald, JR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9057S - 9057S
  • [37] Phase I dose-escalation study of pasireotide LAR in patients with advanced neuroendocrine tumors.
    Phan, Alexandria T.
    Wolin, Edward M.
    Chan, Jennifer A.
    Huang, Jerry M.
    Hudson, Michelle
    Hughes, Gareth
    Shen, Guoxiang
    Strosberg, Jonathan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] A phase I and pharmacokinetic (PK) study of ET-743 evaluating a 3 hours (h) intravenous (iv) infusion (I) in patients (pts) with solid tumors.
    Twelves, C
    Hoeckman, H
    Bowman, A
    Beijnen, JH
    Faber, M
    Guzman, C
    Anthoney, A
    Smyth, J
    Hanauske, AR
    Jimeno, J
    CLINICAL CANCER RESEARCH, 1999, 5 : 3790S - 3791S
  • [39] Phase I study of pazopanib and ixabepilone in patients with solid tumors.
    Ganesan, Chitra
    Obulareddy, J.
    Bliss, Robin L.
    Dudek, Arkadiusz Z.
    CANCER RESEARCH, 2013, 73 (08)
  • [40] A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors.
    Ranson, M.
    Dive, C.
    Ward, T.
    Cummings, J.
    Connolly, K.
    Evans, S.
    Robson, L.
    Durkin, J.
    Jolivet, J.
    Jodrell, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 135S - 135S
12345